Information Provided By:
Fly News Breaks for March 15, 2019
AVEO
Mar 15, 2019 | 08:13 EDT
Baird analyst Madhu Kumar reiterated an Outperform rating and $2 price target on Aveo Pharmaceuticals after the company reported its Q4 earnings report. The analyst said in a research note partially titled "Clinical Basis for TIVO-3 OS Optimism" that he continues to have relative optimism to the Street for Fotivda, and added that a Q4 of 2019 update on TIVO-3 OS was a key potential positive catalyst for the stock.
News For AVEO From the Last 2 Days
There are no results for your query AVEO
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.